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Abstract 
Phosphatidylinositol-3,4,5-trisphosphate RAC exchanger 2a (P-REX2a) is a member of 
the P-REX protein family which are activated by phosphatidylinositol-3,4,5-
trisphosphate that act as Rho/Rac guanine nucleotide exchange factors. P-REX2 was at 
first found to activate the small GTPase Rac, downstream of G protein-coupled receptors 
and phosphoinositide 3-kinase (PI3K) to enhance cell motility. Later, a new role of P-
REX2a had been identified to inhibit the lipid phosphatase activity of PTEN to stimulate 
the PI3K pathway and enhance cell viability, movement and growth.  No associations 
with P-REX2a and human endometrial cancers have been reported to date. In this study, 
we immunohistochemically analyzed 155 uterine endometrial malignancies for P-REX2a 
expression. The P-REX2a-positive tumors displayed worse prognosis independent of 
PTEN expression. Then, we transduced either P-REX2a expression vector or short hairpin 
RNAs targeting P-REX2a into 2 uterine endometrioid carcinoma cell lines, OMC-2 and 
JHUEM-14. Ectopic expression of P-REX2a led to increased cell proliferation only in the 
PTEN-expressing OMC-2 cells but did not show any change in the PTEN-negative 
JHUEM-14 cells or the P-REX2a-knockdown cells. Induction of P-REX2a increased and 
knockdown of P-REX2a decreased cell migration in both cell lines. Then, we performed 
expression microarray analysis using these cells, and pathway analysis revealed that the 
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expression of members of the GPCR downstream pathway displayed the most significant 
changes induced by the knockdown of P-REX2a. Immunohistochemical analysis revealed 
that Vav1, a member of the GPCR downstream pathway, was expressed in 139 of the 155 
endometrial tumors, and the expression levels of Vav1 and P-REX2a showed a positive 
correlation (r=0.44, p<0.001). In conclusion, P-REX2a enhanced cell motility via the 
GPCR downstream pathway independently of PTEN leading to progression of uterine 
endometrioid malignancies and poor prognosis of the patients. 
 
